OLVIG
FBIO icon

Oliver Lagore Vanvalin Investment Group’s Fortress Biotech FBIO Stock Holding History

Oliver Lagore Vanvalin Investment Group’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-27
Closed -$328 – 799
2023
Q1 		$328 Buy
+27
New +$321 ﹤0.01% 665

Other funds holding FBIO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SAM
Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Corient Private Wealth
Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
1WM
1900 Wealth Management San Antonio, Texas $1.56B AUM 14.13% 1-Year Est. Return

Oliver Lagore Vanvalin Investment Group's FBIO Position: Q2 2023 in Review

Oliver Lagore Vanvalin Investment Group sold out of Fortress Biotech (FBIO) in Q2 2023, closing a stake of 27 shares — an estimated $328 sold.

Oliver Lagore Vanvalin Investment Group first reported a position in FBIO in Q1 2023 and held it in 1 quarter. The position peaked at $328 in Q1 2023. 48 funds tracked by Wall St. Rank hold FBIO as of Q2 2023.

  • Oliver Lagore Vanvalin Investment Group reported no remaining Fortress Biotech position as of Q2 2023 after selling out during the quarter.
  • Oliver Lagore Vanvalin Investment Group sold 27 Fortress Biotech shares in Q2 2023, an estimated $328.
  • Oliver Lagore Vanvalin Investment Group first reported a position in Fortress Biotech in Q1 2023 and held it in 1 quarter.
  • Oliver Lagore Vanvalin Investment Group's Fortress Biotech position peaked at $328 in Q1 2023.
  • 48 funds tracked by Wall St. Rank held Fortress Biotech as of Q2 2023.

Based on Oliver Lagore Vanvalin Investment Group's 13F filing for Q2 2023, filed 8 Aug 2023.